Unique Approach Integrates Portfolio Management with Budgeting and Program Oversight for Better Pipeline Management Across Matrix Organizations
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--April 20, 2004-- Artemis International Solutions Corporation (OTCBB:AMSI - News), specialists in portfolio management, today announced the general availability of the Artemis New Product Development solution for Pharmaceutical R&D. The new enterprise portfolio management system is designed to improve pipeline management processes for pharmaceutical and biotechnology firms.
According to Patrick Ternier, president and CEO of Artemis, effective portfolio management in life sciences research and development has been linked to increased profitability by ensuring that resources and capital are effectively distributed in line with business strategy.
"Pharmaceutical companies are facing increased market pressure that must be translated into more effective R&D planning efforts in order to maintain competitiveness. Portfolio management is a well-understood practice in life sciences, but firms still struggle to reach a desirable level of process maturity. A key part of that challenge is a direct consequence of using fragmented systems resulting in the inability to effectively integrate and drive portfolio decisions down to operational execution," added Ternier. "Artemis has 20 years of experience working with leading pharmaceutical companies and has applied this expertise to design a portfolio management solution to meet these challenges."
Artemis was recently chosen by Actelion Pharmaceuticals Ltd to align and prioritize all products in their portfolio with their business strategy in order to maximize investment returns. "We selected Artemis because of their demonstrated experiences in pharmaceutical companies and the accelerated implementation we will get from their New Product Development solution for Pharmaceutical R&D," explained Miriam Halperin-Wernli, head of Business & Science Affairs for Actelion. "We will be supported in proactively managing our entire portfolio of candidates with timely and accurate cost, schedule, risk, and benefit information that was previously distributed across multiple systems. This will help us establish consistency and an improved process, thereby systematizing, simplifying and speeding up decision cycles."
Artemis' New Product Development solution is developed on the company's enterprise portfolio, project and resource management platform, Artemis 7. It consists of pre-configured software, field-tested process templates and standard reports that have been specifically designed for rapid implementation and return on investment in pharmaceutical and biotechnology firms. The Artemis solution for Pharmaceutical R&D is immediately available.
Another early adopter of the Artemis New Product Development solution is Japan-based Kirin Pharmaceutical.
About Artemis International Solutions Corporation
Artemis International Solutions Corporation (OTCBB:AMSI - News) is one of the world's leading providers of investment planning and control solutions that help organizations execute strategy through effective portfolio and project management. Artemis has refined 30 years' experience into a suite of solutions and packaged consulting services that address the specific needs of both industry and the public sector including, IT management, new product development, program management, fleet and asset management, outage management and detailed project management. With a global network covering 44 countries, Artemis is helping thousands of organizations to improve their business performance through better alignment of strategy, investment planning and project execution. For more information, visit www.aisc.com.
Forward Looking Statements
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: This press release contains or may contain forward-looking statements such as statements regarding the Company's growth and profitability, growth strategy, liquidity and access to public markets, operating expense reduction and trends in the industry in which the Company operates. These forward-looking statements are based on current expectations and are subject to a number of risks, uncertainties and assumptions. Important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements are detailed in the documents filed by the Company with the Securities and Exchange Commission including but not limited to those contained under the Risk Factors section of Form 10-K for the year ended December 31, 2001. The Company assumes no obligation to update these forward-looking statements to reflect actual results, changes in risks, uncertainties or assumptions underlying or affecting such statements or for prospective events that may have a retroactive effect.
-------------------------------------------------------------------------------- Contact:
Lages & Associates
Kerry Fedro/Jennifer Tolkachev, 949-453-8080
kerry@lages.com / jennifer@lages.com
--------------------------------------------------------------------------------
Source: Artemis International Solutions Corporation